LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer.
A MandlS JasmineTeg KruegerR KumarI M ColemanS L DalrympleL AntonyD M RosenY JingB HanrattyR A PatelL Jin-YihJ DiasC A CelatkaA E TapperM KleppeM KanayamaV SperanziniY Z WangJ LuoE CoreyL A SenaR A CaseroT LotanB J TrockS K KachhapS R DenmeadeM A CarducciA MatteviM C HaffnerP S NelsonH Y RienhoffJ T IsaacsW Nathaniel BrennenPublished in: bioRxiv : the preprint server for biology (2024)
Neuroendocrine prostate cancer presents a clinical challenge due to the lack of effective treatments. Our research demonstrates that bomedemstat, a potent and selective LSD1 inhibitor, effectively combats neuroendocrine prostate cancer by downregulating the ASCL1- dependent NE transcriptional program and re-expressing YAP1.